Ironwood Pharmaceuticals
IRWD
208 hedge funds and large institutions have $2.24B invested in Ironwood Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 75 increasing their positions, 66 reducing their positions, and 31 closing their positions.
388% more call options, than puts
Call options by funds: $14.6M | Put options by funds: $3M
17% more capital invested
Capital invested by funds: $1.91B → $2.24B (+$333M)
14% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 66
1.42% more ownership
Funds ownership: 106.33% → 107.75% (+1.4%)
3% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 31
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% less funds holding
Funds holding: 209 → 208 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
+$38.8M |
| 2 |
Goldman Sachs
New York
|
+$16.6M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$15.9M |
| 4 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$12.7M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$20.6M |
| 2 |
BlackRock
New York
|
-$20.6M |
| 3 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$19.3M |
| 4 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$12.4M |
| 5 |
BM
Bridger Management
New York
|
-$9.36M |
IRWD Hedge Fund Activity: Q2 2021 in Review
208 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q2 2021, worth a combined $2.24B — up 17% from $1.91B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new IRWD positions and 31 closed out — a net gain of 1 holder — while 75 added to existing stakes and 66 trimmed.
The largest buyer was LSV Asset Management, adding an estimated $38.8M. The largest seller was Vanguard Group, cutting an estimated $20.6M.
- 208 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q2 2021, down from 209 in Q1 2021.
- Funds reported $2.24B of Ironwood Pharmaceuticals stock for Q2 2021, up 17% quarter-over-quarter.
- 32 funds opened new Ironwood Pharmaceuticals positions in Q2 2021 and 31 closed out, a net change of +1 holder.
- The largest Ironwood Pharmaceuticals buyer in Q2 2021 was LSV Asset Management, an estimated $38.8M added.
- The largest Ironwood Pharmaceuticals seller in Q2 2021 was Vanguard Group, an estimated $20.6M sold.
Based on aggregated 13F filings for Q2 2021.